RGX-202 met the main goal of a Phase 3 DMD trial, and Regenxbio plans to seek accelerated approval for the gene therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results